Effi-7
- Generic Name
- Effi-7
Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- OSE Immunotherapeutics
- Target Recruit Count
- 150
- Registration Number
- NCT04882007
- Locations
- 🇷🇺
Ekaterinburg City Clinical Hospital No. 14, Ekaterinburg, Russian Federation
🇧🇪Groupe Santé CHC - Clinique du Mont Légia, Liège, Belgium
🇧🇬Medical Center Medconsult Pleven - OOD, Pleven, Bulgaria
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- OSE Immunotherapeutics
- Target Recruit Count
- 63
- Registration Number
- NCT03980080
- Locations
- 🇧🇪
SGS Life Sciences (SGS LS), Clinical Pharmacology Unit (CPU), Antwerp, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath